What is Exagen?
Exagen is a United States-based life sciences entity dedicated to enhancing healthcare through advanced diagnostic testing solutions. The company's primary focus is on autoimmune diseases, offering a suite of laboratory tests, notably under its AVISE brand, designed to aid healthcare providers in the accurate diagnosis, prognosis, and monitoring of conditions such as lupus and rheumatoid arthritis. By leveraging proprietary biomarkers and innovative testing technologies, Exagen aims to provide critical clarity for clinical decision-making, thereby enabling more effective treatment strategies and improving patient outcomes through continuous research-driven innovation.
How much funding has Exagen raised?
Exagen has raised a total of $258.3M across 15 funding rounds:
Series D
$5M
Debt
$25M
Debt
$4M
Debt
$1.8M
Debt
$3M
Series E
$16.8M
Debt
$2.1M
Series F
$23M
Debt
$25M
Private Equity
$22.6M
Stock Offering
$58M
Stock/Share Issuance
$20.2M
Series D (2013): $5M featuring CRG L.P.
Debt (2013): $25M backed by Capital Royalty Partners
Debt (2014): $4M with participation from Sun Mountain Capital
Debt (2015): $1.8M, investors not publicly disclosed
Debt (2015): $3M, investors not publicly disclosed
Series E (2016): $16.8M, investors not publicly disclosed
Debt (2016): $2.1M, investors not publicly disclosed
Series F (2017): $23M, investors not publicly disclosed
Debt (2017): $25M led by Innovatus Capital Partners, LLC
Private Equity (2019): $22.6M supported by H.I.G. BioHealth Partners, Sun Mountain, Tullis Health Funds, and Hunt Holdings
Stock Issuance/Offering (2019): $58M featuring Undisclosed
Stock/Share Issuance (2025): $20.2M, investors not publicly disclosed
Key Investors in Exagen
CRG L.P.
CRG L.P. is a global investment firm focused on enhancing healthcare through flexible growth capital solutions, specializing in credit and select equity investments across consumer health, life sciences, and healthcare services & IT.
Tullis Health Investors
Tullis Health Investors is a private equity firm that specializes in investing in high-growth, commercial-stage healthcare companies, focusing on medical devices, healthcare services and technology, specialty pharmaceuticals, and biotechnology to build long-term value.
Sun Mountain Capital
Sun Mountain Capital is a private equity firm with investment strategies in both direct investment and fund of funds programs spanning venture capital, private credit and growth equity, headquartered in Santa Fe, New Mexico.
What's next for Exagen?
With a substantial total funding of $258.3M and a recent major strategic investment of $20.2M, Exagen is well-positioned for its next phase of growth. The company's consistent access to capital, including various debt and equity rounds over the years, indicates strong investor confidence in its diagnostic technologies and market strategy. This sustained financial backing suggests a focus on scaling operations, further developing its product pipeline, and potentially expanding into new therapeutic areas or geographical markets. The company's trajectory points towards solidifying its role as a leader in autoimmune disease diagnostics, driven by ongoing innovation and strategic financial partnerships.
See full Exagen company page
